Table 1 Clinical features baseline data
From: Novel nomogram to predict the overall survival of postoperative patients with gastric signet
| Â | SEER training set | SEER internal validation set | External validation set | P value | Method |
|---|---|---|---|---|---|
n (%) | n (%) | n (%) | |||
Total | 3079 (68.1%) | 1319 (29.2%) | 124 (2.7%) | Â | Â |
Fustat |  < 0.001 | Chisq test | |||
 Death | 905 (20%) | 442 (9.8%) | 66 (1.5%) |  |  |
 Alive | 2174 (48.1%) | 877 (19.4%) | 58 (1.3%) |  |  |
 Futime, median (IQR) | 720 (270, 1620) | 630 (240, 1560) | 1650 (690, 2377.5) |  < 0.001 | Kruskal–Wallis |
Age |  < 0.001 | Chisq test | |||
 ≥ 70 | 1032 (22.8%) | 427 (9.4%) | 5 (0.1%) |  |  |
 < 70 | 2047 (45.3%) | 892 (19.7%) | 119 (2.6%) |  |  |
Gender | 0.010 | Chisq test | |||
 Female | 1509 (33.4%) | 601 (13.3%) | 47 (1%) |  |  |
 Male | 1570 (34.7%) | 718 (15.9%) | 77 (1.7%) |  |  |
Primary |  < 0.001 | Yates' correction | |||
 Cardia | 443 (9.8%) | 206 (4.6%) | 5 (0.1%) |  |  |
 Fundus of stomach | 74 (1.6%) | 39 (0.9%) | 2 (0%) |  |  |
 Body of stomach | 324 (7.2%) | 139 (3.1%) | 18 (0.4%) |  |  |
 Gastric antrum | 865 (19.1%) | 361 (8%) | 65 (1.4%) |  |  |
 Pylorus | 139 (3.1%) | 52 (1.1%) | 1 (0%) |  |  |
 Lesser curvature of stomach | 366 (8.1%) | 191 (4.2%) | 8 (0.2%) |  |  |
 Greater curvature of stomach | 178 (3.9%) | 77 (1.7%) | 4 (0.1%) |  |  |
 Overlapping lesion of stomach | 357 (7.9%) | 130 (2.9%) | 6 (0.1%) |  |  |
 Stomach-NOS | 333 (7.4%) | 124 (2.7%) | 15 (0.3%) |  |  |
Stage |  < 0.001 | Chisq test | |||
 Stage I | 874 (19.3%) | 333 (7.4%) | 30 (0.7%) |  |  |
 Stage II | 591 (13.1%) | 268 (5.9%) | 28 (0.6%) |  |  |
 Stage III | 785 (17.4%) | 318 (7%) | 46 (1%) |  |  |
 Stage IV | 829 (18.3%) | 400 (8.8%) | 20 (0.4%) |  |  |
T | 0.019 | Chisq test | |||
 T1 | 572 (12.6%) | 208 (4.6%) | 17 (0.4%) |  |  |
 T2 | 1253 (27.7%) | 530 (11.7%) | 56 (1.2%) |  |  |
 T3 | 897 (19.8%) | 416 (9.2%) | 45 (1%) |  |  |
 T4 | 357 (7.9%) | 165 (3.6%) | 6 (0.1%) |  |  |
N | 0.308 | Chisq test | |||
 0 | 953 (21.1%) | 386 (8.5%) | 33 (0.7%) |  |  |
 1 | 1094 (24.2%) | 483 (10.7%) | 43 (1%) |  |  |
 2 | 704 (15.6%) | 282 (6.2%) | 32 (0.7%) |  |  |
 3 | 328 (7.3%) | 168 (3.7%) | 16 (0.4%) |  |  |
M |  < 0.001 | Chisq test | |||
 M0 | 2645 (58.5%) | 1110 (24.5%) | 122 (2.7%) |  |  |
 M1 | 434 (9.6%) | 209 (4.6%) | 2 (0%) |  |  |
RNE | 0.006 | Chisq test | |||
 < 15 | 1436 (31.8%) | 596 (13.2%) | 40 (0.9%) |  |  |
 ≥ 15 | 1643 (36.3%) | 723 (16%) | 84 (1.9%) |  |  |
LNMR |  < 0.001 | Chisq test | |||
 0 | 1006 (22.2%) | 401 (8.9%) | 34 (0.8%) |  |  |
 < 30% | 683 (15.1%) | 310 (6.9%) | 45 (1.0%) |  |  |
 ≥ 30% and < 70% | 679 (15%) | 301 (6.7%) | 22 (0.5%) |  |  |
 ≥ 70% | 711 (15.7%) | 307 (6.8%) | 23 (0.5%) |  |  |
Chemotherapy | N/A | N/A | |||
 Chemotherapy | N/A | N/A | 74 (59.7%) |  |  |
 No chemotherapy | N/A | N/A | 50 (40.3%) |  |  |